Slide 1: Presentation at Biotech Invest 2016 (ASX cover letter)
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au For personal use only 4 May 2016 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (12 pages by email) Dear Madam PRESENTATION AT BIO
Slide 2: Biotron Limited – Singapore and Asia Biotech Invest 2016
For personal use only BIOTRON LIMITED (ASX:BIT) Singapore Biotech Invest 2016 Asia Biotech Invest 2016
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presenta,on may contain forward-‐looking statements with respect to the financial condi,on, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec,ves of its management. These stateme
Slide 4: Biotron Limited Overview
Biotron Limited Overview • Clinical stage drug development company For personal use only • Drug development plaWorm for new class of an,viral drugs • Phase 2 clinical programs for Hepa,,s C virus (HCV) and HIV-‐1 • Earlier stage programs include Dengue, Influenza and others • Headquartered in Sydney
Slide 5: Biotron's Core Technology
Biotron’s Core Technology For personal use only OTHER “HITS” IN LIBRARY include: Designed library of Compounds screened in compounds to target proprietary assay set up for viroporins: each virus target e.g. HIV-‐1 -‐ Influenza A and B Vpu; HCV p7; Influenza M2; -‐ Coronaviruses IniZally >250 compou
Slide 6: BIT225 – First of a New Class of HCV DAA Drugs
BIT225 – First of a New Class of HCV DAA Drugs For personal use only ü Novel, oral, small molecule compound POLYMERASE/PROTEASE INHIBITORS e.g. Sofosbuvir/Simeprevir ü Only one of its class (p7 inhibitor) in clinical trials ü Inhibits viral assembly and infec,vity BIT225 -‐ ASSEMBLY/ BUDDING INH
Slide 7: Positioning BIT225 within HCV Landscape
PosiZoning BIT225 within HCV Landscape • HCV market predicted to earn US$36 billion in 2018 For personal use only • 180 million infected worldwide (3% world popula,on) • Recent new HCV drug combina,ons are good, but not op,mal • Lengthy treatment – 12 weeks or more • Not pan-‐genotypic – BIT225 is
Slide 8: HIV-1: Towards a Cure
HIV-‐1: Towards a Cure • HIV-‐1 remains hidden in reservoirs, leading to chronic, life-‐ For personal use only long infec,on – Invisible to body’s immune defenses – Not sensi,ve to an,-‐HIV-‐1 drugs • Pa,ents need to stay on an,retroviral drugs to keep virus levels under control • Long-‐term h
Slide 9: Unlocking Value for Other Virus Targets
Unlocking Value for Other Virus Targets • Renewed industry interest in targe,ng viral diseases including For personal use only • Respiratory syncy,al virus (RSV) • Hepa,,s B virus • Tropical diseases including Dengue • Influenza (in par,cular drug resistant strains) • Ebola and MERS-‐CoV outbreaks h
Slide 10: Dengue Virus Program
Dengue Virus Program • 2.5 billion people (40% world popula,on) live in areas at risk For personal use only of Dengue • ~100 million people infected yearly • A leading cause of illness and death in tropics and subtropics • Transmission is by mosquito; most preven,on programs target the vector • No a
Slide 11: Financial Information
Financial InformaZon Key Financial Metrics 6 Month Share Price Performance For personal use only Ticker Code ASX: BIT Share Price (29/04/16) A $0.063 Ticker Code ASX: BIT Market cap A $20 million Share Price (15 Sept 2014) A $0.115 12 Month Trading Range A $0.041 – 0.150 Market cap A $26.3 million S
Slide 12: Dr Michelle Miller, Managing Director
For personal use only Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au